PLATCOV is a phase 2 platform study assessing antivirals in early COVID-19 disease. It is looking for sites to be able to rapidly set up and recruit into this platform trial within 4 months, for an 18 month period. The study is run out of the Mahidol Oxford Tropical Medicine Research Unit in Bangkok, Thailand, led by Professor Sir Nicholas White and sponsored by the University of Oxford. The study has funding and is ready to begin.

The coalition convened a meeting of the coalition’s expert working groups with key funders to present projects developed in response to a shortlist of identified priority research questions.

All members were invited to attend the COVID-19 Clinical Research Coalition’s Members Assembly in June, a large participatory online event that was convened for the first time a year after launching the coalition.

The coalition’s Maternal, Newborn, and Child Health Working Group conducted a research priority-setting exercise to identify global research priorities in maternal, reproductive and child health. Members of the working group shared the results in this webinar.

Group of emergency physicians advocates rapid and simple measures to reduce medical oxygen wastage in crisis context of insufficient oxygen.

An article published today in The Lancet calls for urgent collaboration and coordination for unmet, underfunded COVID-19 research priorities in low-resource settings.

This meeting brought together global research funders with the community of researchers who are actively undertaking this research across low- and middle-income countries.

In this webinar, experts and members of the Clinical Epidemiology Working Group give a brief overview of the response to the COVID-19 pandemic from resource-limited settings.

A letter was published this week in The Lancet by four authors who are members of the COVID-19 Clinical Research Coalition. Prof. Nick White, Dr Nathalie Strub-Wourgaft, Prof. Abul Faiz, and Prof. Philippe Guérin make the case that assessments of drug efficacy in preventing COVID-19 and treating uncomplicated COVID-19 should not be based on data pooled with the treatment results of severely ill patients. The authors, who are also members of the coalition’s Steering Committee, note that studies to date have found major differences in therapeutic responses according to disease stage.

The Medicine Quality Research Group has published a new Medical Product Quality Report focusing on increasing issues around substandard and falsified COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.